Overview

Evaluate Efficacy and Safety of Extended Release (ER) Naproxen Sodium

Status:
Completed
Trial end date:
2011-09-01
Target enrollment:
Participant gender:
Summary
The objective is to evaluate pain relief of the extended release naproxen sodium 660 mg tablet compared to commercial naproxen sodium 220 mg tablet over 24 hours in patients with postsurgical dental pain.
Phase:
Phase 3
Details
Lead Sponsor:
Bayer
Treatments:
Naproxen